Testing Arm 2- Budesonide (Pulmicort® for pneumonitis

Exclusion

• −Use of a medication with significant interaction with inhaled budesonide (HIV protease inhibitors, ketoconazole or other potent CYP3A4 inhibitors), unless deemed required and safe by co-investigatorPrincipal investigatorThe doctor or researcher responsible for running the study at a site.Read more →.
• −Diagnosis of interstitial lung disease (ILD) active (clinically and radiologically evident) within last year prior to diagnosis of CIP
• −Clinically suspected significant lung disease for which inhaled steroid would be standard of careStandard of careThe treatment normally given for a condition outside a study.Read more → (moderate asthma or severe chronic obstructive pulmonary disease (COPD)) and for which randomizationRandomisedWhich group you go into is decided by chance, not by you or your doctor.Read more → to no inhaled steroids (control armControl groupThe group a new treatment is measured against.Read more →) would not represent optimal medical care. Based on enrolling physicians judgement; spirometry/pulmonary function tests are NOT required to assess this exclusion criteriaExclusion criteriaThe things that would prevent someone from taking part.Read more →.
• −Current (within last two weeks), active (not medically able or unwilling to discontinue prior to treatment start) and regular (2 or more times per week) use of inhaled steroids (for any indication) or systemic (\>10mg prednisone equivalent) corticosteroids (for indication other than CIP) at time of randomization
• −Known poorly controlled diabetes, defined as A1c \>10, prior to initiation of steroids for CIP
• −History of active and unstable systemic disease, including heart failure New York Heart Association (NYHA) III or IV, cirrhosis with Child Pugh B or C, Renal Failure with creatinine clearance (CrCl) \<30 per Cockcroft-Gault formula, or other unstable life limiting condition as determined by trial investigators
• −Current or prior participation in a study of an investigational agent or device within 4 weeks of randomization
• −History or current evidence of any condition, therapy, or laboratory abnormalities which might confound trial results, interfere with the patient's participation for the full duration of the trial, or otherwise causing it to be not in the best interest of the patient to participate in the trial, in the opinion of the treating investigator.
• −Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is directly involved with this trial, unless prospective ethics board approval (by chair or designee) is given allowing exception to this criterion for a specific patient
• −Breastfeeding is not permitted during the duration of trial participation.
• −Receiving systemic, non-chemotherapy immunosuppressive agent at time of randomization (hydroxychloroquine is acceptable)